IPO
StartX Med company Kodiak Sciences, a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases, recently reached a market cap of $3.56 billion.
Recipharm, the contract development and manufacturing organisation, has invested USD 450,000 into its Research Triangle Park, North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
Ardelyx, Inc. has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
4TEEN4 Pharmaceuticals GmbH announced the closing of a EUR 6.9 million Series A financing round.
Fundraising will support the expansion of Hummingbird Bioscience’s discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics
Bpifrance and Pfizer Ventures co-led international investor syndicate
The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies
Since its foundation Cambridge Innovation Capital has attracted £1 billion of investment into Cambridge companies, highlighting its dominant position at the heart of the innovation ecosystem
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
Liminal BioSciences Inc. has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).
PRESS RELEASES